Savant Capital LLC Cuts Stock Holdings in Exact Sciences Corporation $EXAS

Savant Capital LLC lowered its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 58.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,919 shares of the medical research company’s stock after selling 22,816 shares during the quarter. Savant Capital LLC’s holdings in Exact Sciences were worth $846,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Great Lakes Advisors LLC raised its stake in Exact Sciences by 3.7% in the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after purchasing an additional 178 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its holdings in shares of Exact Sciences by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after buying an additional 187 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Exact Sciences by 0.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock valued at $3,127,000 after buying an additional 217 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Exact Sciences by 6.5% in the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock worth $237,000 after buying an additional 273 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Exact Sciences by 37.0% during the second quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock worth $54,000 after acquiring an additional 275 shares during the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Stock Down 0.9%

EXAS stock opened at $67.75 on Friday. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $72.81. The firm has a market cap of $12.84 billion, a PE ratio of -12.48, a PEG ratio of 5.56 and a beta of 1.34. The firm’s 50 day moving average price is $59.57 and its 200-day moving average price is $54.03. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. During the same quarter last year, the firm earned ($0.21) earnings per share. The firm’s quarterly revenue was up 20.0% compared to the same quarter last year. Exact Sciences has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Guggenheim increased their price objective on shares of Exact Sciences from $70.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Evercore ISI increased their price target on Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Zacks Research raised Exact Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Piper Sandler upped their target price on Exact Sciences from $70.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Craig Hallum raised their target price on Exact Sciences from $65.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $74.06.

Insider Transactions at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the completion of the transaction, the executive vice president owned 22,368 shares of the company’s stock, valued at $1,567,549.44. This trade represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the sale, the director directly owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.20% of the stock is currently owned by company insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.